Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Avalo Therapeutics (AVTX) EBT (2016 - 2025)

Avalo Therapeutics filings provide 12 years of EBT readings, the most recent being -$13.6 million for Q4 2025.

  • On a quarterly basis, EBT rose 61.42% to -$13.6 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$78.1 million, a 123.03% decrease, with the full-year FY2025 number at -$78.1 million, down 123.03% from a year prior.
  • EBT hit -$13.6 million in Q4 2025 for Avalo Therapeutics, up from -$30.6 million in the prior quarter.
  • In the past five years, EBT ranged from a high of $98.5 million in Q2 2024 to a low of -$121.3 million in Q1 2024.
  • Median EBT over the past 5 years was -$13.4 million (2025), compared with a mean of -$13.5 million.
  • The widest YoY moves for EBT: up 1302.91% in 2024, down 1119.29% in 2024.
  • Avalo Therapeutics' EBT stood at -$19.1 million in 2021, then surged by 48.8% to -$9.8 million in 2022, then grew by 16.6% to -$8.2 million in 2023, then crashed by 330.78% to -$35.2 million in 2024, then skyrocketed by 61.42% to -$13.6 million in 2025.
  • The last three reported values for EBT were -$13.6 million (Q4 2025), -$30.6 million (Q3 2025), and -$20.7 million (Q2 2025) per Business Quant data.